Tirzepatide — 10mg

Description

Tirzepatide’s dual mechanism makes it fundamentally different from GLP-1-only compounds. While GLP-1 receptor agonism handles appetite regulation and glucose management, GIP receptor activation works directly on adipocytes to enhance fat oxidation and improve energy storage patterns. At the 10mg dose, both pathways are operating at therapeutic capacity. Clinical data from the SURMOUNT trials shows dose-dependent fat loss, with 10mg producing ~19% average body weight reduction.

For women, the 10mg dose becomes relevant after completing a 4-8 week titration period from 2.5mg and 5mg. Hormonal context matters: women tend to experience better tolerability than men at equivalent doses, and many find 10mg produces significant appetite reduction without requiring higher doses. In perimenopausal women, where insulin resistance is compounding hormonal-driven fat redistribution, the 10mg dose addresses both the metabolic and adipose-storage components simultaneously.

Female-calibrated dosing: Typically reached after 8 weeks on 5mg (titrated from 2.5mg). Inject 10mg subcutaneously once weekly. Many women maintain at 10mg indefinitely; others continue to 15mg if clinically warranted. Rotate injection sites (abdomen, thigh, upper arm). Do not inject into muscle.

Storage: Store lyophilized powder below -20°C. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution.